French biopharmaceutical Osivax, which is developing vaccines to provide broad-spectrum protection against highly mutating ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

TOKYO - As the cost of ramen ingredients has risen, ramen shops in Japan have found themselves beset by tough business conditions. Many of them are reluctant to raise prices, lest they run afoul of ...

Q4 2024 Earnings Call Transcript March 6, 2025 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported ...

We are very pleased to have recently received European Commission approval for KOSTAIVE® and MHLW approval for Meiji Seika Pharma and ARCALIS to add commercial manufacturing sites in Japan.

On the manufacturing front, Meiji Seika Pharma, our Japanese vaccine partner, submitted a manufacturing and marketing application in February for a new vial presentation of KOSTAIVE provided in a ...

Osivax secures strategic funding to accelerate the development of its influenza vaccine candidates: Lyon, France Wednesday, March 5, 2025, 16:00 Hrs [IST] Osivax, a biopharmaceuti ...

Newron to participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 am PDT.

The company is pleased to welcome Meiji Seika Pharma Co., Ltd, a leading Japanese pharmaceutical company specializing in infectious diseases, as a new investor. With a legacy spanning over 75 ...

Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing ...